Cochrane Abstracts
Intravenous beta2‐agonists versus intravenous aminophylline for acute asthma
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Intravenous Beta2‐agonists Versus Intravenous Aminophylline for Acute Asthma." Cochrane Abstracts, John Wiley & Sons, Inc, 2025. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/434376/2/Intravenous_beta2‐agonists_versus_intravenous_aminophylline_for_acute_asthma.
Intravenous beta2‐agonists versus intravenous aminophylline for acute asthma. Cochrane Abstracts. John Wiley & Sons, Inc; 2025. https://evidence.unboundmedicine.com/evidence/view/Cochrane/434376/2/Intravenous_beta2‐agonists_versus_intravenous_aminophylline_for_acute_asthma. Accessed September 21, 2025.
Intravenous beta2‐agonists versus intravenous aminophylline for acute asthma. (2025). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/434376/2/Intravenous_beta2‐agonists_versus_intravenous_aminophylline_for_acute_asthma
Intravenous Beta2‐agonists Versus Intravenous Aminophylline for Acute Asthma [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2025. [cited 2025 September 21]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/434376/2/Intravenous_beta2‐agonists_versus_intravenous_aminophylline_for_acute_asthma.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Intravenous beta2‐agonists versus intravenous aminophylline for acute asthma
ID - 434376
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/434376/2/Intravenous_beta2‐agonists_versus_intravenous_aminophylline_for_acute_asthma
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
